Acorda, Amgen, Insys, Pfizer, Roche, Hayman Capital Management autoimmune news
The U.S. Patent Trial and Appeal Board instituted inter partes (IPR) review petitions from hedge fund manager Kyle Bass against four of the five patents covering Acorda’s Ampyra dalfampridine for multiple sclerosis. If all of the patents’ claims are invalidated, Acorda would be left with one patent covering Ampyra: U.S. Patent No. 5,540,938, which expires in 2018. Bass challenged U.S. Patents Nos. 8,663,685; 8,007,826; 8,440,703; and 8,354,437, which cover composition and dosing of an aminopyridine compound to treat neurological disorders. PTAB determined that there is a reasonable likelihood that the coalition could demonstrate that their claims are unpatentable. The last of the four expires in 2027. Acorda said it expects a ruling from PTAB within a year. Ampyra is a sustained-release formulation of 4-aminopyridine (4-AP). ...